Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Reading disability

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    25 result(s) found for: Reading disability. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2019-000419-98 Sponsor Protocol Number: B4Z-US-LYEI Start Date*: 2021-12-13
    Sponsor Name:Eli Lilly and Company
    Full Title: Neurophysiology of Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Dyslexia: Functional Magnetic Resonance Imaging (fMRI) Measures of Brain Activation During Attention and Reading Tas...
    Medical condition: Attention Deficit Hyperactivity Disorder, Dyslexia.
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004873 10003735 Attention deficit-hyperactivity disorder LLT
    20.0 10029205 - Nervous system disorders 10013932 Dyslexia PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2020-005929-89 Sponsor Protocol Number: CLOU064C12302 Start Date*: 2022-02-01
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by...
    Medical condition: Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) GR (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) SI (Trial now transitioned) SK (Trial now transitioned) BG (Trial now transitioned) PL (Trial now transitioned) HR (Trial now transitioned) EE (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-005899-36 Sponsor Protocol Number: CLOU064C12301 Start Date*: 2022-02-21
    Sponsor Name:Novartis Pharma AG
    Full Title: A randomized, double-blind, double-dummy, parallel-group study, comparing the efficacy and safety of remibrutinib versus teriflunomide in participants with relapsing multiple sclerosis, followed by...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) BE (Trial now transitioned) BG (Trial now transitioned) LV (Trial now transitioned) HR (Trial now transitioned) LT (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-003384-30 Sponsor Protocol Number: IR902-231 Start Date*: 2007-02-26
    Sponsor Name:The Immune Response Corporation
    Full Title: A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for Multiple Sclerosis
    Medical condition: Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001202-34 Sponsor Protocol Number: PK-NAF-RMN Start Date*: 2016-05-04
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
    Full Title: A preliminary, multicenter study on the relationship between cortical damage and blood brain barrier damage in Multiple Sclerosis patients with high cortical disease activity. Correlation between [...
    Medical condition: Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10039720 Sclerosis multiple LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-012500-11 Sponsor Protocol Number: 205MS301 Start Date*: 2010-04-12
    Sponsor Name:Biogen Idec Ltd
    Full Title: Multicenter, Double-blind, Randomized, Parallel-group, Monotherapy, Active-control Study to Determine the Efficacy and Safety of Daclizumab High Yield Process (DAC HYP) versus Avonex® (Interferon β...
    Medical condition: Relapsing-remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Completed) FR (Completed) DE (Completed) CZ (Completed) HU (Completed) FI (Completed) SE (Completed) ES (Completed) GB (Completed) GR (Completed) IT (Completed) DK (Completed) SI (Completed)
    Trial results: View results
    EudraCT Number: 2018-001718-13 Sponsor Protocol Number: MP18 Start Date*: 2019-10-18
    Sponsor Name:MAPS Europe B.V.
    Full Title: An Open- Label, Phase 2, Multicenter Feasibility Study if Manualized MDMA-Assisted Psychotherapy with an fMRI sub-study Assessing Changes in Brain Activity in Subjects with Posttraumatic Stress Dis...
    Medical condition: post-traumatic stress disorder (PTSD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) CZ (Completed) NO (Completed) DE (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000395-26 Sponsor Protocol Number: GER-BGT-13-10586 Start Date*: 2015-08-07
    Sponsor Name:Biogen GmbH
    Full Title: A 3-year open-label, exploratory, single arm study to describe long term changes in the visual system of patients with relapsing remitting multiple sclerosis (RRMS) on oral dimethyl fumarate
    Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-003925-23 Sponsor Protocol Number: PIANISSIMO Start Date*: 2023-04-12
    Sponsor Name:Vrije Universiteit Brussel
    Full Title: Pain medication tapering for patients with Persistent Spinal Pain Syndrome Type II, treated with Spinal Cord Stimulation.
    Medical condition: Persistent spinal pain syndrome type 2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-003733-14 Sponsor Protocol Number: WA17823 Start Date*: 2005-03-23
    Sponsor Name:F. Hoffmann La-Roche Ltd.
    Full Title: A randomized, double-blind, parallel group study of the safety and prevention of structural joint damage during treatment with MRA versus placebo, in combination with methotrexate, in patients with...
    Medical condition: Rheumatoid Arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) DK (Completed) IT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2006-004834-33 Sponsor Protocol Number: ROB 803-09-002 Start Date*: 2007-07-05
    Sponsor Name:OxyPharma AB
    Full Title: A Phase II, Randomised, Double-blind, International, Multicentre, Placebo-controlled, Dose-ranging, Parallel-group Study to Evaluate the Efficacy and Safety of Orally Administered Rob 803 when Adde...
    Medical condition: Rheumatiod Arthritis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039073 Rheumatoid arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) LV (Completed) GB (Completed) BE (Completed) BG (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006786-92 Sponsor Protocol Number: AC-058B201 Start Date*: 2009-06-18
    Sponsor Name:Actelion Pharmaceuticals Ltd
    Full Title: Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose finding study to evaluate the efficacy, safety, and tolerability of three doses of ACT-128800, an oral S1P1 receptor ...
    Medical condition: relapsing-remitting multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) FI (Completed) FR (Completed) GB (Completed) ES (Completed) SE (Completed) HU (Completed) NL (Completed) PL (Completed) IT (Completed) AT (Completed) BE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-001449-26 Sponsor Protocol Number: 6603/1132 Start Date*: 2015-01-22
    Sponsor Name:Seikagaku Corporation
    Full Title: A Multicenter, Open-label Study of SI-6603 in Patients with Lumbar Disc Herniation (Phase III)
    Medical condition: Lumbar disc herniation
    Disease: Version SOC Term Classification Code Term Level
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10050296 Intervertebral disc protrusion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003423-30 Sponsor Protocol Number: 2017-RCT-OX Start Date*: 2017-12-12
    Sponsor Name:Dutch Growth Research Foundation
    Full Title: Randomized, double-blind, placebo-controlled oxytocin and dose-response trial in children with Prader-Willi syndrome. Effects on social behaviour.
    Medical condition: Prader-Willi syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10036476 Prader-Willi syndrome PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-000504-37 Sponsor Protocol Number: 2020PI215 Start Date*: 2021-04-01
    Sponsor Name:CHRU DE NANCY
    Full Title: Characterization by PET-CT with 18F-FDG of brain lesions in young subjects with sequential psycho-cognitive disorders following severe COVID19
    Medical condition: young subjects with sequential psycho-cognitive disorders in the aftermath of severe COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004863 10084547 Exposure to COVID-19 LLT
    21.1 10029205 - Nervous system disorders 10057668 Cognitive disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000568-41 Sponsor Protocol Number: GS-US-417-0301 Start Date*: 2016-10-11
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to ...
    Medical condition: Moderately to severely active rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) GB (Completed) BE (Completed) HU (Completed) CZ (Completed) DE (Completed) ES (Completed) BG (Completed) PL (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000570-37 Sponsor Protocol Number: GS-US-417-0303 Start Date*: 2016-11-29
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Randomized, Double-blind, Placebo-and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination with Methotr...
    Medical condition: Moderately to severely active rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) BE (Completed) GB (Completed) HU (Completed) DE (Completed) CZ (Completed) ES (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2019-000797-39 Sponsor Protocol Number: 201790 Start Date*: 2019-11-22
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study comparing GSK3196165 with placebo and with tofacitinib, in combination with methotrexate in participants with mo...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) LV (Completed) ES (Completed) PL (Completed) LT (Completed) CZ (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001135-12 Sponsor Protocol Number: 204812 Start Date*: 2016-10-27
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase II, randomised, observer-blind, controlled, multi-country study to rank different formulations of GSK Biologicals’ investigational RSV vaccine (GSK3003891A), based on immunogenicity, reacto...
    Medical condition: Respiratory Syncytial Virus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10061603 Respiratory syncytial virus infection PT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed) EE (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-000867-26 Sponsor Protocol Number: 201791 Start Date*: 2019-12-10
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A 52-week, phase 3, multicentre, randomised, double blind, efficacy and safety study, comparing GSK3196165 with placebo and with tofacitinib in combination with conventional synthetic DMARDs, in pa...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) PL (Prematurely Ended) BG (Prematurely Ended) EE (Completed) HU (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 12:59:08 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA